Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fluorobenzenes | 16 | 2014 | 19 | 2.520 |
Why?
|
Sulfonamides | 16 | 2014 | 65 | 2.440 |
Why?
|
Pyrimidines | 16 | 2014 | 60 | 2.400 |
Why?
|
Heptanoic Acids | 10 | 2014 | 28 | 1.590 |
Why?
|
Pyrroles | 10 | 2014 | 55 | 1.550 |
Why?
|
Myocardial Infarction | 16 | 2016 | 413 | 1.520 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 17 | 2011 | 126 | 1.460 |
Why?
|
Hypercholesterolemia | 10 | 2010 | 59 | 1.250 |
Why?
|
Simvastatin | 10 | 2011 | 25 | 1.160 |
Why?
|
Cholesterol, LDL | 14 | 2009 | 157 | 1.140 |
Why?
|
Anticholesteremic Agents | 6 | 2012 | 36 | 1.100 |
Why?
|
Treatment Outcome | 41 | 2018 | 3100 | 1.090 |
Why?
|
Middle Aged | 76 | 2019 | 10834 | 1.050 |
Why?
|
Stents | 9 | 2018 | 171 | 1.040 |
Why?
|
Aged | 68 | 2019 | 9492 | 0.980 |
Why?
|
Pulmonary Embolism | 2 | 2015 | 46 | 0.980 |
Why?
|
Humans | 107 | 2019 | 29119 | 0.940 |
Why?
|
Cardiovascular Diseases | 6 | 2014 | 1017 | 0.940 |
Why?
|
Femoral Artery | 6 | 2017 | 44 | 0.920 |
Why?
|
Female | 84 | 2019 | 18173 | 0.890 |
Why?
|
Urinary Incontinence, Stress | 6 | 2005 | 64 | 0.880 |
Why?
|
Male | 72 | 2019 | 17815 | 0.780 |
Why?
|
Platelet Aggregation | 2 | 2019 | 21 | 0.760 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2016 | 82 | 0.730 |
Why?
|
Time Factors | 25 | 2018 | 2001 | 0.720 |
Why?
|
Retrospective Studies | 40 | 2018 | 3112 | 0.710 |
Why?
|
Health Resources | 2 | 2018 | 33 | 0.660 |
Why?
|
Prostheses and Implants | 4 | 2005 | 41 | 0.630 |
Why?
|
Adult | 33 | 2019 | 8425 | 0.610 |
Why?
|
Risk Factors | 24 | 2018 | 3537 | 0.610 |
Why?
|
Thrombolytic Therapy | 2 | 2015 | 59 | 0.610 |
Why?
|
Opioid-Related Disorders | 1 | 2018 | 50 | 0.600 |
Why?
|
Thrombectomy | 2 | 2015 | 58 | 0.600 |
Why?
|
Drug Resistance | 1 | 2016 | 36 | 0.580 |
Why?
|
Stroke | 5 | 2016 | 548 | 0.570 |
Why?
|
Aspirin | 1 | 2016 | 62 | 0.570 |
Why?
|
Dyslipidemias | 2 | 2014 | 52 | 0.560 |
Why?
|
Catheterization, Peripheral | 2 | 2017 | 24 | 0.550 |
Why?
|
Heart Neoplasms | 2 | 2014 | 14 | 0.540 |
Why?
|
Analgesics, Opioid | 2 | 2018 | 239 | 0.540 |
Why?
|
Embolectomy | 1 | 2015 | 3 | 0.530 |
Why?
|
Myocarditis | 1 | 2015 | 6 | 0.530 |
Why?
|
Clozapine | 1 | 2015 | 4 | 0.530 |
Why?
|
Thrombosis | 2 | 2015 | 60 | 0.530 |
Why?
|
Brain Ischemia | 1 | 2016 | 136 | 0.530 |
Why?
|
Antipsychotic Agents | 1 | 2015 | 26 | 0.520 |
Why?
|
Heart Valve Prosthesis Implantation | 4 | 2018 | 41 | 0.510 |
Why?
|
Bone Wires | 1 | 2014 | 11 | 0.500 |
Why?
|
Sternotomy | 1 | 2014 | 3 | 0.500 |
Why?
|
Hemangioma | 1 | 2014 | 18 | 0.490 |
Why?
|
Sutures | 1 | 2014 | 19 | 0.490 |
Why?
|
Aortic Valve | 4 | 2018 | 47 | 0.490 |
Why?
|
Coronary Artery Disease | 6 | 2019 | 360 | 0.490 |
Why?
|
Heart Diseases | 1 | 2015 | 99 | 0.490 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2014 | 60 | 0.480 |
Why?
|
Postural Balance | 2 | 2016 | 160 | 0.480 |
Why?
|
Polyesters | 1 | 2014 | 72 | 0.480 |
Why?
|
Suture Techniques | 1 | 2014 | 56 | 0.480 |
Why?
|
Huntington Disease | 3 | 2018 | 14 | 0.480 |
Why?
|
Pesticides | 2 | 2016 | 189 | 0.460 |
Why?
|
Occupational Exposure | 2 | 2016 | 224 | 0.450 |
Why?
|
Drugs, Generic | 2 | 2010 | 13 | 0.450 |
Why?
|
Drug-Eluting Stents | 5 | 2011 | 16 | 0.450 |
Why?
|
Emigrants and Immigrants | 2 | 2016 | 235 | 0.440 |
Why?
|
Transients and Migrants | 2 | 2016 | 281 | 0.440 |
Why?
|
Liver Neoplasms | 1 | 2014 | 162 | 0.440 |
Why?
|
Coronary Restenosis | 5 | 2011 | 13 | 0.430 |
Why?
|
Oseltamivir | 1 | 2012 | 6 | 0.430 |
Why?
|
Disease Outbreaks | 1 | 2012 | 35 | 0.420 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2012 | 49 | 0.410 |
Why?
|
Aorta, Abdominal | 1 | 2011 | 26 | 0.400 |
Why?
|
Antiviral Agents | 1 | 2012 | 100 | 0.400 |
Why?
|
Cesarean Section | 4 | 2010 | 82 | 0.400 |
Why?
|
Iliac Artery | 1 | 2011 | 46 | 0.400 |
Why?
|
Preventive Health Services | 1 | 2011 | 30 | 0.400 |
Why?
|
Intra-Aortic Balloon Pumping | 1 | 2010 | 6 | 0.380 |
Why?
|
Intraoperative Complications | 2 | 2010 | 49 | 0.370 |
Why?
|
Influenza, Human | 1 | 2012 | 122 | 0.370 |
Why?
|
Electric Countershock | 1 | 2010 | 10 | 0.370 |
Why?
|
Pravastatin | 3 | 2008 | 12 | 0.370 |
Why?
|
Risk Assessment | 16 | 2018 | 1306 | 0.370 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2010 | 21 | 0.370 |
Why?
|
United States | 19 | 2019 | 3632 | 0.360 |
Why?
|
Lipoproteins, LDL | 1 | 2010 | 77 | 0.360 |
Why?
|
Hispanic Americans | 2 | 2016 | 904 | 0.350 |
Why?
|
Cardiac Surgical Procedures | 1 | 2010 | 71 | 0.350 |
Why?
|
Blood Vessel Prosthesis Implantation | 4 | 2011 | 68 | 0.340 |
Why?
|
Chorea | 2 | 2018 | 2 | 0.330 |
Why?
|
Multivariate Analysis | 6 | 2018 | 637 | 0.330 |
Why?
|
Aortic Valve Insufficiency | 2 | 2018 | 24 | 0.330 |
Why?
|
Urologic Surgical Procedures | 2 | 2005 | 60 | 0.320 |
Why?
|
Heart Valve Prosthesis | 2 | 2018 | 53 | 0.320 |
Why?
|
Postoperative Complications | 6 | 2019 | 670 | 0.320 |
Why?
|
Bioprosthesis | 2 | 2018 | 55 | 0.320 |
Why?
|
Chi-Square Distribution | 3 | 2018 | 293 | 0.320 |
Why?
|
Databases, Factual | 5 | 2018 | 332 | 0.300 |
Why?
|
Aged, 80 and over | 15 | 2019 | 3719 | 0.290 |
Why?
|
Follow-Up Studies | 15 | 2019 | 2109 | 0.290 |
Why?
|
Quality of Life | 6 | 2018 | 816 | 0.280 |
Why?
|
Cost-Benefit Analysis | 11 | 2013 | 159 | 0.280 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2018 | 64 | 0.280 |
Why?
|
India | 4 | 2014 | 61 | 0.280 |
Why?
|
Coronary Angiography | 4 | 2015 | 136 | 0.270 |
Why?
|
Coronary Disease | 5 | 2007 | 200 | 0.270 |
Why?
|
Fascia Lata | 1 | 2005 | 2 | 0.270 |
Why?
|
Solvents | 1 | 2005 | 4 | 0.270 |
Why?
|
Urinary Retention | 1 | 2005 | 6 | 0.270 |
Why?
|
Dermis | 1 | 2005 | 12 | 0.270 |
Why?
|
Dehydration | 1 | 2005 | 7 | 0.270 |
Why?
|
Incidence | 9 | 2019 | 1119 | 0.260 |
Why?
|
Age Factors | 6 | 2018 | 1108 | 0.260 |
Why?
|
Uterine Prolapse | 1 | 2005 | 21 | 0.260 |
Why?
|
Transplantation, Heterologous | 1 | 2005 | 121 | 0.260 |
Why?
|
Vascular Diseases | 4 | 2011 | 61 | 0.260 |
Why?
|
Urinary Catheterization | 1 | 2004 | 14 | 0.250 |
Why?
|
Fibrinolytic Agents | 3 | 2015 | 70 | 0.250 |
Why?
|
Hemorrhage | 3 | 2016 | 91 | 0.240 |
Why?
|
Combined Modality Therapy | 6 | 2011 | 525 | 0.240 |
Why?
|
Postoperative Care | 1 | 2004 | 72 | 0.240 |
Why?
|
Coronary Artery Bypass | 3 | 2013 | 100 | 0.240 |
Why?
|
Endarterectomy, Carotid | 1 | 2003 | 29 | 0.240 |
Why?
|
Heart Atria | 2 | 2014 | 62 | 0.240 |
Why?
|
Angioplasty, Balloon | 1 | 2003 | 33 | 0.240 |
Why?
|
Prostatic Neoplasms | 5 | 2005 | 441 | 0.230 |
Why?
|
Computer Simulation | 3 | 2014 | 207 | 0.230 |
Why?
|
Mitral Valve Insufficiency | 2 | 2013 | 21 | 0.230 |
Why?
|
Radial Artery | 2 | 2013 | 15 | 0.220 |
Why?
|
Proportional Hazards Models | 6 | 2016 | 709 | 0.220 |
Why?
|
Cohort Studies | 13 | 2017 | 1688 | 0.210 |
Why?
|
Logistic Models | 6 | 2018 | 727 | 0.210 |
Why?
|
Coronary Thrombosis | 4 | 2010 | 15 | 0.210 |
Why?
|
Severity of Illness Index | 8 | 2018 | 863 | 0.210 |
Why?
|
Immunoglobulin Fab Fragments | 3 | 2006 | 14 | 0.210 |
Why?
|
Delivery, Obstetric | 4 | 2005 | 50 | 0.200 |
Why?
|
Acute Coronary Syndrome | 4 | 2011 | 175 | 0.200 |
Why?
|
Models, Biological | 2 | 2014 | 373 | 0.190 |
Why?
|
Platelet Function Tests | 2 | 2019 | 6 | 0.190 |
Why?
|
Immunosuppressive Agents | 3 | 2019 | 167 | 0.190 |
Why?
|
Pelvis | 3 | 2005 | 61 | 0.190 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2013 | 136 | 0.180 |
Why?
|
Metals | 3 | 2010 | 16 | 0.180 |
Why?
|
Antibodies, Monoclonal | 3 | 2006 | 196 | 0.180 |
Why?
|
Pulmonary Artery | 2 | 2018 | 23 | 0.180 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2019 | 6 | 0.180 |
Why?
|
Electrocardiography | 4 | 2012 | 568 | 0.170 |
Why?
|
Atherosclerosis | 3 | 2010 | 698 | 0.170 |
Why?
|
ABO Blood-Group System | 1 | 2019 | 19 | 0.170 |
Why?
|
Blood Platelets | 1 | 2019 | 37 | 0.170 |
Why?
|
Thromboembolism | 1 | 2019 | 30 | 0.170 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 246 | 0.170 |
Why?
|
Young Adult | 3 | 2018 | 2402 | 0.170 |
Why?
|
Prosthesis Failure | 1 | 2018 | 43 | 0.170 |
Why?
|
Aortic Valve Stenosis | 1 | 2018 | 28 | 0.170 |
Why?
|
Anticoagulants | 3 | 2016 | 122 | 0.170 |
Why?
|
Patients | 1 | 2018 | 46 | 0.160 |
Why?
|
Hirudins | 2 | 2016 | 19 | 0.160 |
Why?
|
Pulmonary Valve | 1 | 2018 | 10 | 0.160 |
Why?
|
Heart Valve Diseases | 1 | 2018 | 25 | 0.160 |
Why?
|
Aneurysm | 1 | 2018 | 21 | 0.160 |
Why?
|
Tetrabenazine | 1 | 2018 | 3 | 0.160 |
Why?
|
Pain, Postoperative | 2 | 2014 | 174 | 0.160 |
Why?
|
Prosthesis Design | 4 | 2018 | 87 | 0.160 |
Why?
|
Lovastatin | 4 | 2011 | 6 | 0.160 |
Why?
|
Case-Control Studies | 5 | 2016 | 859 | 0.160 |
Why?
|
Heparin | 2 | 2016 | 75 | 0.160 |
Why?
|
Double-Blind Method | 3 | 2014 | 502 | 0.150 |
Why?
|
Hemodynamics | 2 | 2018 | 148 | 0.150 |
Why?
|
Medication Adherence | 1 | 2019 | 144 | 0.150 |
Why?
|
Caregivers | 1 | 2018 | 94 | 0.150 |
Why?
|
Dopamine Agents | 1 | 2017 | 19 | 0.150 |
Why?
|
Ohio | 1 | 2016 | 54 | 0.150 |
Why?
|
Vascular Surgical Procedures | 1 | 2017 | 91 | 0.150 |
Why?
|
Coronary Occlusion | 1 | 2016 | 1 | 0.150 |
Why?
|
Comparative Effectiveness Research | 2 | 2016 | 23 | 0.140 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2007 | 35 | 0.140 |
Why?
|
Disease-Free Survival | 1 | 2016 | 281 | 0.140 |
Why?
|
Twins, Monozygotic | 2 | 2006 | 11 | 0.140 |
Why?
|
North Carolina | 4 | 2016 | 1423 | 0.140 |
Why?
|
Physicians | 1 | 2018 | 134 | 0.140 |
Why?
|
Piperidines | 1 | 2017 | 125 | 0.140 |
Why?
|
Anilides | 2 | 2005 | 7 | 0.140 |
Why?
|
Saphenous Vein | 2 | 2005 | 20 | 0.140 |
Why?
|
Androgen Antagonists | 2 | 2005 | 15 | 0.130 |
Why?
|
Antineoplastic Agents | 2 | 2014 | 546 | 0.130 |
Why?
|
Schizophrenia, Paranoid | 1 | 2015 | 2 | 0.130 |
Why?
|
Cardiotonic Agents | 2 | 2013 | 39 | 0.130 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2005 | 32 | 0.130 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2015 | 2 | 0.130 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 22 | 0.130 |
Why?
|
Peptides | 2 | 2006 | 118 | 0.130 |
Why?
|
Ventricular Function, Left | 2 | 2013 | 195 | 0.130 |
Why?
|
Peptide Fragments | 2 | 2016 | 422 | 0.130 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2015 | 24 | 0.130 |
Why?
|
Image Enhancement | 1 | 2015 | 70 | 0.130 |
Why?
|
Prostate-Specific Antigen | 2 | 2005 | 61 | 0.130 |
Why?
|
Fecal Incontinence | 2 | 2005 | 21 | 0.130 |
Why?
|
Pregnancy | 5 | 2010 | 815 | 0.130 |
Why?
|
Phenylurea Compounds | 1 | 2014 | 11 | 0.130 |
Why?
|
Niacinamide | 1 | 2014 | 8 | 0.130 |
Why?
|
Suction | 1 | 2014 | 13 | 0.130 |
Why?
|
Magnetic Resonance Imaging | 2 | 2015 | 1219 | 0.130 |
Why?
|
Gynecologic Surgical Procedures | 2 | 2005 | 41 | 0.120 |
Why?
|
Steel | 1 | 2014 | 2 | 0.120 |
Why?
|
Diabetes Complications | 2 | 2008 | 171 | 0.120 |
Why?
|
Enoxaparin | 1 | 2014 | 19 | 0.120 |
Why?
|
Myocardial Ischemia | 1 | 2015 | 83 | 0.120 |
Why?
|
Fatal Outcome | 1 | 2014 | 78 | 0.120 |
Why?
|
Heart Failure | 3 | 2018 | 571 | 0.120 |
Why?
|
Vena Cava, Inferior | 1 | 2014 | 31 | 0.120 |
Why?
|
Angiography | 1 | 2014 | 75 | 0.120 |
Why?
|
Drainage | 1 | 2014 | 49 | 0.120 |
Why?
|
Sex Distribution | 2 | 2012 | 186 | 0.120 |
Why?
|
Hydrazones | 1 | 2013 | 3 | 0.120 |
Why?
|
Pyridazines | 1 | 2013 | 7 | 0.120 |
Why?
|
Pregnancy, Multiple | 2 | 2003 | 7 | 0.120 |
Why?
|
Equipment Design | 1 | 2014 | 167 | 0.120 |
Why?
|
Echocardiography | 1 | 2014 | 140 | 0.120 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 189 | 0.120 |
Why?
|
Surgical Wound Infection | 1 | 2014 | 74 | 0.120 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 172 | 0.110 |
Why?
|
Hospital Costs | 1 | 2013 | 36 | 0.110 |
Why?
|
Cardiopulmonary Bypass | 2 | 2013 | 57 | 0.110 |
Why?
|
Nitriles | 3 | 2007 | 22 | 0.110 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 493 | 0.110 |
Why?
|
Preoperative Care | 3 | 2013 | 110 | 0.110 |
Why?
|
Hospitals, Public | 1 | 2012 | 5 | 0.110 |
Why?
|
Hospitals, Private | 1 | 2012 | 9 | 0.110 |
Why?
|
Sex Factors | 2 | 2012 | 631 | 0.110 |
Why?
|
Atherectomy | 1 | 2011 | 4 | 0.100 |
Why?
|
Morbidity | 1 | 2011 | 91 | 0.100 |
Why?
|
Age Distribution | 1 | 2012 | 198 | 0.100 |
Why?
|
Adult Stem Cells | 1 | 2011 | 24 | 0.100 |
Why?
|
Bone Marrow Transplantation | 1 | 2011 | 65 | 0.100 |
Why?
|
Azetidines | 1 | 2011 | 8 | 0.100 |
Why?
|
Tissue Plasminogen Activator | 1 | 2011 | 40 | 0.100 |
Why?
|
Health Care Costs | 2 | 2010 | 108 | 0.100 |
Why?
|
Niacin | 1 | 2011 | 7 | 0.100 |
Why?
|
Laser Therapy | 1 | 2011 | 52 | 0.100 |
Why?
|
Medical Records Systems, Computerized | 2 | 2007 | 21 | 0.100 |
Why?
|
Odds Ratio | 6 | 2007 | 447 | 0.100 |
Why?
|
Risk Reduction Behavior | 1 | 2011 | 116 | 0.100 |
Why?
|
Prospective Studies | 3 | 2019 | 2021 | 0.100 |
Why?
|
Hospital Mortality | 3 | 2009 | 186 | 0.090 |
Why?
|
Adhesives | 1 | 2010 | 2 | 0.090 |
Why?
|
Triglycerides | 2 | 2008 | 214 | 0.090 |
Why?
|
Breast Neoplasms | 2 | 2007 | 666 | 0.090 |
Why?
|
Population | 1 | 2009 | 8 | 0.090 |
Why?
|
Hypoglycemic Agents | 1 | 2011 | 176 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2011 | 118 | 0.090 |
Why?
|
Professional Practice | 1 | 2009 | 23 | 0.090 |
Why?
|
Parity | 2 | 2006 | 12 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2010 | 464 | 0.090 |
Why?
|
Health Expenditures | 1 | 2010 | 61 | 0.090 |
Why?
|
Emergency Medical Services | 1 | 2011 | 157 | 0.090 |
Why?
|
Down-Regulation | 1 | 2009 | 143 | 0.090 |
Why?
|
Patient Compliance | 1 | 2011 | 208 | 0.090 |
Why?
|
Exercise Test | 2 | 2015 | 194 | 0.090 |
Why?
|
Exercise Therapy | 1 | 2011 | 229 | 0.080 |
Why?
|
Diet | 1 | 2011 | 355 | 0.080 |
Why?
|
Hospitalization | 1 | 2012 | 417 | 0.080 |
Why?
|
Secondary Prevention | 2 | 2008 | 59 | 0.080 |
Why?
|
British Columbia | 1 | 2008 | 1 | 0.080 |
Why?
|
Diastole | 2 | 2008 | 90 | 0.080 |
Why?
|
Prevalence | 6 | 2009 | 898 | 0.080 |
Why?
|
Apolipoproteins B | 1 | 2008 | 44 | 0.080 |
Why?
|
Posture | 1 | 2008 | 53 | 0.080 |
Why?
|
Vagina | 2 | 2005 | 47 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2011 | 342 | 0.080 |
Why?
|
Apolipoprotein A-I | 1 | 2008 | 68 | 0.080 |
Why?
|
Adolescent | 3 | 2012 | 3254 | 0.080 |
Why?
|
Pulmonary Edema | 1 | 2008 | 7 | 0.080 |
Why?
|
Urodynamics | 2 | 2005 | 34 | 0.080 |
Why?
|
Immunization Programs | 1 | 2008 | 26 | 0.080 |
Why?
|
Lipids | 1 | 2009 | 209 | 0.080 |
Why?
|
Cholesterol, HDL | 1 | 2008 | 165 | 0.080 |
Why?
|
Medicare | 1 | 2009 | 186 | 0.080 |
Why?
|
Recurrence | 2 | 2005 | 235 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2008 | 42 | 0.080 |
Why?
|
Length of Stay | 3 | 2017 | 292 | 0.080 |
Why?
|
Hypertriglyceridemia | 1 | 2007 | 7 | 0.080 |
Why?
|
Urinary Incontinence, Urge | 1 | 2007 | 2 | 0.080 |
Why?
|
Triazoles | 1 | 2007 | 14 | 0.070 |
Why?
|
Angina, Unstable | 1 | 2006 | 17 | 0.070 |
Why?
|
Coated Materials, Biocompatible | 1 | 2006 | 17 | 0.070 |
Why?
|
Suburethral Slings | 1 | 2007 | 11 | 0.070 |
Why?
|
Urinary Bladder, Overactive | 1 | 2007 | 14 | 0.070 |
Why?
|
Tamoxifen | 1 | 2007 | 48 | 0.070 |
Why?
|
Lung | 1 | 2008 | 233 | 0.070 |
Why?
|
Echocardiography, Doppler | 2 | 2005 | 39 | 0.070 |
Why?
|
Hemostasis, Surgical | 1 | 2006 | 13 | 0.070 |
Why?
|
Urinary Incontinence | 2 | 2004 | 45 | 0.070 |
Why?
|
Hemostatic Techniques | 1 | 2006 | 7 | 0.070 |
Why?
|
Contrast Media | 1 | 2006 | 124 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2007 | 180 | 0.070 |
Why?
|
Lumbosacral Plexus | 1 | 2005 | 5 | 0.070 |
Why?
|
Flutamide | 1 | 2005 | 5 | 0.070 |
Why?
|
Postoperative Hemorrhage | 1 | 2006 | 38 | 0.070 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2005 | 9 | 0.070 |
Why?
|
Hyperlipidemias | 1 | 2006 | 50 | 0.070 |
Why?
|
Pelvic Pain | 1 | 2005 | 18 | 0.070 |
Why?
|
Leukocyte Count | 1 | 2005 | 55 | 0.070 |
Why?
|
Cyanates | 1 | 2005 | 1 | 0.070 |
Why?
|
Dyspareunia | 1 | 2005 | 7 | 0.070 |
Why?
|
Foreign-Body Reaction | 1 | 2005 | 5 | 0.070 |
Why?
|
Respiration, Artificial | 3 | 2013 | 96 | 0.070 |
Why?
|
Cross-Linking Reagents | 1 | 2005 | 16 | 0.070 |
Why?
|
Rectocele | 1 | 2005 | 2 | 0.070 |
Why?
|
Colposcopy | 1 | 2005 | 4 | 0.070 |
Why?
|
Sexual Behavior | 1 | 2006 | 97 | 0.070 |
Why?
|
Renal Insufficiency | 1 | 2005 | 53 | 0.070 |
Why?
|
Probability | 4 | 2006 | 150 | 0.070 |
Why?
|
Nerve Block | 1 | 2005 | 48 | 0.060 |
Why?
|
Death, Sudden, Cardiac | 1 | 2005 | 59 | 0.060 |
Why?
|
Diabetic Angiopathies | 1 | 2005 | 137 | 0.060 |
Why?
|
Patient Care Planning | 1 | 2005 | 53 | 0.060 |
Why?
|
Valsalva Maneuver | 1 | 2004 | 3 | 0.060 |
Why?
|
Life Tables | 1 | 2004 | 4 | 0.060 |
Why?
|
Swine | 1 | 2005 | 201 | 0.060 |
Why?
|
Sirolimus | 3 | 2011 | 35 | 0.060 |
Why?
|
Actinomycosis | 1 | 2004 | 2 | 0.060 |
Why?
|
Paclitaxel | 3 | 2011 | 50 | 0.060 |
Why?
|
Recovery of Function | 2 | 2018 | 190 | 0.060 |
Why?
|
Dimethyl Sulfoxide | 1 | 2004 | 10 | 0.060 |
Why?
|
Cystitis | 1 | 2004 | 8 | 0.060 |
Why?
|
Eosinophilia | 1 | 2004 | 16 | 0.060 |
Why?
|
Reoperation | 1 | 2005 | 203 | 0.060 |
Why?
|
Electromyography | 1 | 2004 | 58 | 0.060 |
Why?
|
Punctures | 2 | 2017 | 32 | 0.060 |
Why?
|
Cost of Illness | 1 | 2004 | 63 | 0.060 |
Why?
|
Myocardial Revascularization | 3 | 2010 | 37 | 0.060 |
Why?
|
Collagen | 1 | 2005 | 217 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2006 | 239 | 0.060 |
Why?
|
Coronary Stenosis | 1 | 2003 | 28 | 0.060 |
Why?
|
Puerperal Disorders | 1 | 2003 | 6 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2006 | 337 | 0.060 |
Why?
|
Managed Care Programs | 3 | 2008 | 38 | 0.060 |
Why?
|
Carotid Stenosis | 1 | 2003 | 56 | 0.060 |
Why?
|
Blood Vessel Prosthesis | 1 | 2003 | 78 | 0.060 |
Why?
|
Registries | 3 | 2011 | 278 | 0.060 |
Why?
|
Self Care | 1 | 2004 | 137 | 0.060 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2005 | 190 | 0.060 |
Why?
|
Prognosis | 4 | 2009 | 1362 | 0.060 |
Why?
|
Hypertension, Portal | 1 | 2002 | 9 | 0.060 |
Why?
|
Obesity | 1 | 2010 | 1063 | 0.060 |
Why?
|
Liver Failure | 1 | 2002 | 17 | 0.060 |
Why?
|
Hypertension, Pulmonary | 1 | 2002 | 23 | 0.060 |
Why?
|
Fibroma | 1 | 2002 | 11 | 0.050 |
Why?
|
Mothers | 1 | 2003 | 79 | 0.050 |
Why?
|
Comorbidity | 3 | 2010 | 540 | 0.050 |
Why?
|
Health Status | 1 | 2004 | 368 | 0.050 |
Why?
|
Recombinant Proteins | 2 | 2016 | 248 | 0.050 |
Why?
|
Calcinosis | 1 | 2003 | 143 | 0.050 |
Why?
|
Stroke Volume | 3 | 2011 | 279 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2003 | 298 | 0.050 |
Why?
|
Academic Medical Centers | 2 | 2013 | 150 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2011 | 18 | 0.050 |
Why?
|
Kidney Transplantation | 1 | 2005 | 352 | 0.050 |
Why?
|
Reference Values | 3 | 2006 | 224 | 0.050 |
Why?
|
Drug Therapy, Combination | 3 | 2006 | 273 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2008 | 787 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2017 | 641 | 0.050 |
Why?
|
Depression | 2 | 2018 | 382 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2003 | 368 | 0.040 |
Why?
|
Survival Rate | 3 | 2006 | 795 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2007 | 1379 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 2 | 2010 | 23 | 0.040 |
Why?
|
Fatty Acids, Monounsaturated | 2 | 2008 | 9 | 0.040 |
Why?
|
Indoles | 2 | 2008 | 58 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2011 | 263 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2019 | 222 | 0.040 |
Why?
|
Perception | 1 | 2018 | 92 | 0.040 |
Why?
|
Health Services Research | 2 | 2008 | 78 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2009 | 140 | 0.040 |
Why?
|
Canada | 1 | 2017 | 49 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2018 | 239 | 0.040 |
Why?
|
Patient Discharge | 1 | 2017 | 168 | 0.040 |
Why?
|
Survival Analysis | 2 | 2010 | 440 | 0.040 |
Why?
|
Tosyl Compounds | 2 | 2005 | 4 | 0.030 |
Why?
|
Regression Analysis | 2 | 2006 | 274 | 0.030 |
Why?
|
Postmenopause | 2 | 2007 | 397 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 1362 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2005 | 454 | 0.030 |
Why?
|
Animals | 1 | 2005 | 7299 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2005 | 532 | 0.030 |
Why?
|
Intensive Care Units | 1 | 2013 | 118 | 0.030 |
Why?
|
American Heart Association | 1 | 2012 | 84 | 0.030 |
Why?
|
Connective Tissue | 1 | 2011 | 4 | 0.030 |
Why?
|
Sweden | 1 | 2011 | 14 | 0.030 |
Why?
|
Propensity Score | 1 | 2011 | 34 | 0.030 |
Why?
|
Microinjections | 1 | 2011 | 33 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2011 | 55 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2011 | 113 | 0.030 |
Why?
|
Rural Health Services | 1 | 2011 | 27 | 0.030 |
Why?
|
Medical Records | 1 | 2011 | 68 | 0.030 |
Why?
|
Myocardium | 1 | 2011 | 170 | 0.020 |
Why?
|
Retreatment | 1 | 2010 | 40 | 0.020 |
Why?
|
Insurance Claim Review | 1 | 2010 | 27 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 2010 | 46 | 0.020 |
Why?
|
Eligibility Determination | 1 | 2009 | 14 | 0.020 |
Why?
|
International Classification of Diseases | 1 | 2009 | 26 | 0.020 |
Why?
|
Lung Compliance | 1 | 2008 | 8 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2009 | 68 | 0.020 |
Why?
|
Angina Pectoris | 1 | 2008 | 19 | 0.020 |
Why?
|
Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2008 | 2 | 0.020 |
Why?
|
Organizational Case Studies | 1 | 2008 | 11 | 0.020 |
Why?
|
Platelet Count | 1 | 2008 | 21 | 0.020 |
Why?
|
Hematocrit | 1 | 2008 | 23 | 0.020 |
Why?
|
Models, Organizational | 1 | 2008 | 17 | 0.020 |
Why?
|
Hemoglobins | 1 | 2008 | 42 | 0.020 |
Why?
|
Leukocytes | 1 | 2008 | 52 | 0.020 |
Why?
|
Goals | 1 | 2007 | 36 | 0.020 |
Why?
|
Medical Audit | 1 | 2007 | 14 | 0.020 |
Why?
|
Treatment Failure | 1 | 2007 | 159 | 0.020 |
Why?
|
Acute Disease | 1 | 2008 | 239 | 0.020 |
Why?
|
Platelet Activation | 1 | 2006 | 12 | 0.020 |
Why?
|
Markov Chains | 1 | 2007 | 25 | 0.020 |
Why?
|
Drug Costs | 1 | 2007 | 42 | 0.020 |
Why?
|
Creatinine | 1 | 2007 | 174 | 0.020 |
Why?
|
Automation | 1 | 2006 | 30 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2006 | 38 | 0.020 |
Why?
|
Injections | 1 | 2006 | 61 | 0.020 |
Why?
|
Pilot Projects | 1 | 2008 | 469 | 0.020 |
Why?
|
Counseling | 1 | 2007 | 85 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2007 | 163 | 0.020 |
Why?
|
Twin Studies as Topic | 1 | 2006 | 1 | 0.020 |
Why?
|
National Health Programs | 1 | 2006 | 4 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2006 | 10 | 0.020 |
Why?
|
Equipment Safety | 1 | 2006 | 20 | 0.020 |
Why?
|
Premenopause | 1 | 2006 | 38 | 0.020 |
Why?
|
Program Evaluation | 1 | 2006 | 175 | 0.020 |
Why?
|
Bupivacaine | 1 | 2005 | 48 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2008 | 374 | 0.020 |
Why?
|
Postoperative Period | 1 | 2005 | 91 | 0.020 |
Why?
|
Health Surveys | 1 | 2005 | 191 | 0.020 |
Why?
|
Linear Models | 1 | 2006 | 426 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2005 | 57 | 0.020 |
Why?
|
Anesthetics, Local | 1 | 2005 | 77 | 0.020 |
Why?
|
Prostatectomy | 1 | 2005 | 79 | 0.020 |
Why?
|
Urethra | 1 | 2005 | 100 | 0.020 |
Why?
|
Child, Preschool | 1 | 2008 | 1167 | 0.020 |
Why?
|
Urination Disorders | 1 | 2004 | 5 | 0.020 |
Why?
|
Administration, Intravesical | 1 | 2004 | 22 | 0.020 |
Why?
|
Hematuria | 1 | 2004 | 7 | 0.020 |
Why?
|
Cystoscopy | 1 | 2004 | 26 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2005 | 104 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2004 | 40 | 0.020 |
Why?
|
Triplets | 1 | 2003 | 1 | 0.020 |
Why?
|
Twins | 1 | 2003 | 3 | 0.020 |
Why?
|
Pain Measurement | 1 | 2005 | 364 | 0.020 |
Why?
|
Northwestern United States | 1 | 2003 | 1 | 0.010 |
Why?
|
Dobutamine | 1 | 2003 | 43 | 0.010 |
Why?
|
Adenosine | 1 | 2003 | 42 | 0.010 |
Why?
|
Vasodilator Agents | 1 | 2003 | 54 | 0.010 |
Why?
|
Anxiety | 1 | 2004 | 159 | 0.010 |
Why?
|
Congresses as Topic | 1 | 2003 | 37 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2004 | 436 | 0.010 |
Why?
|
Decision Making | 1 | 2005 | 180 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2003 | 165 | 0.010 |
Why?
|
Chronic Disease | 1 | 2004 | 370 | 0.010 |
Why?
|
Systole | 1 | 2002 | 87 | 0.010 |
Why?
|
Body Mass Index | 1 | 2005 | 865 | 0.010 |
Why?
|
Echocardiography, Transesophageal | 1 | 2002 | 40 | 0.010 |
Why?
|
Disease Progression | 1 | 2004 | 572 | 0.010 |
Why?
|
Liver Transplantation | 1 | 2002 | 111 | 0.010 |
Why?
|
Hypertension | 1 | 2008 | 910 | 0.010 |
Why?
|
Blood Pressure | 1 | 2002 | 806 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2003 | 871 | 0.010 |
Why?
|